In a paper by Moorkens and Barcina Lacosta et al., the authors examine how several factors, especially regional-level differences in policy measures and practices, influence uptake of TNF-α inhibitor biosimilars in Germany [5]. Findings were based on a literature review, analysis of ambulatory dispensing data provided by the German Institute for Drug Use Evaluation (DAPI) and interviews investigating prescribers’ and insurers’ views in Germany.

Market shares of both biosimilar infliximab and etanercept varied widely between the 17 German Regional Associations of Statutory Health Insurance Accredited Physicians (PA regions), 33%‒87% and 33%‒77%, respectively in the last quarter of 2018. Quantitative analyses showed that biosimilar market shares for infliximab and etanercept were significantly lower in former East Germany when compared to former West Germany regions.

Through the qualitative analysis of interview data, the authors identified a set of incentives potentially driving biosimilar use. Relatively high price differences between the biosimilar and the originator product after discounts/rebates were regarded as a driver for increased biosimilar use. Price effects could not be evaluated in more detail, as information on discounted/rebated prices was not publicly available. Experts also highlighted the influence of prescription and budget control activities (organized at the regional and insurer level) on the variable uptake of infliximab and etanercept biosimilars across Germany. The use of biosimilars has been found to be primarily influenced by the regional-level implementation of biosimilar quotas, the presence of an effective monitoring and sanctioning system to regulate adherence to biosimilar quotas, the effectiveness of the communication between regional physician associations and individual prescribers, the different conditions for discount contracts established at the insurer-manufacturer level and the organization of initiatives for gainsharing.

Conflict of interest
The authors of the research paper [5] declared that there was no conflict of interest.

Abstracted by Teresa Barcina, PhD Researcher Market Dynamics and Sustainability of off-patent biologics and biosimilar medicines, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.

Editor’s comment
Readers interested to learn more about pricing and reimbursement policies for biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.7 – CiteScore 2019 (calculated on 6 May 2020)
2.0 – CiteScoreTracker 2020 (Last updated on 10 January 2021)

Related articles
Quotas improve biosimilar use in Germany

Automatic pharmacist substitution of biosimilars in Germany

References
1. Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: Part 1-biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285-97.
2. Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: Part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299-306.
3. Blankart KE, Arndt F. Physician-level cost control measures and regional variation of biosimilar utilization in Germany. Int J Environ Res Public Health. 2020;17(11):4113.
4. Schwabe U, Paffrath D, Ludwig WD, et al. Arzneiverordnungs-Report 2019; Springer Berlin Heidelberg: 2019.
5. Moorkens E, Barcina Lacosta T, Vulto AG, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals (Basel) 2020;13(10):324.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

10 January 2021